Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Olomouc – page 30

376 clinical trials in Olomouc, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Olomouc at a glance
376
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

376 trials in Olomouc

Open in trial search

Hormone-refractory prostate cancer

Not recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Novartis Pharma AG

Cervix carcinoma

Not recruiting

Study Comparing Tisotumab Vedotin with Chemotherapy for Patients with Recurrent or Metastatic Cervical Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:Seagen Inc.

Colorectal cancer metastatic

Not recruiting

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Venetoclax and Dexamethasone with Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Gastrointestinal stromal tumour

Not recruiting

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Cogent Biosciences Inc.

Renal cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Oesophageal carcinoma

Not recruiting

Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Bladder cancer

Not recruiting

Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Olomouc

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple cancer types, including metastatic prostate cancer, lung cancer, and colorectal cancer. Research emphasizes innovative treatment approaches and combination therapies.

  • Prostate Cancer Treatment Evaluation
  • Lung Cancer Therapy Development
  • Cervical Cancer Treatment Comparisons

These trials aim to improve survival rates and treatment effectiveness across various cancer types.

02 Cardiovascular and Metabolic Disorders

Studies investigating treatments for heart failure prevention, obesity management, and cardiovascular disease. Focus on innovative therapeutic approaches and combination treatments.

  • Heart Failure Prevention Studies
  • Obesity Treatment Research
  • Cardiovascular Risk Management

Research aims to reduce cardiovascular events and improve patient outcomes.

03 Immunology and Inflammatory Conditions

Clinical investigations targeting Crohn's disease, chronic rhinosinusitis, and other inflammatory conditions. Studies evaluate novel therapeutic approaches and treatment optimization.

  • Inflammatory Bowel Disease Therapy
  • Autoimmune Disease Treatment
  • Infection Management Studies

Research focuses on improving treatment responses and patient quality of life.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.